Dr Aung Pyae Phyo
Aung Pyae Phyo
Aung Pyae Phyo, a Burmese (Myanmar) clinician, finished medical training in 2001 in Yangon. He joined the Shoklo Malaria Research Unit in 2005 where he has led the cohort which unearthed the emergence of artemisinins resistance on the Thai-Myanmar border in 2010.
Afterwards, he pursued research on the Artemisinin Combination Therapy resistant malaria as well as the trials on the new antimalarial compounds such as OZ439 (Artefenomel), KAF156 (Ganaplacide) and KAE609 (Cipargamin).
In 2017 Aung Pyae Phyo completed his Doctor of Philosophy in Clinical Medicine at Oxford University. After completing the DPhil, he joined the Myanmar Oxford Clinical Research Unit in Yangon, Myanmar where his focus is malaria elimination and surveillance of the spread of drug resistant malaria in Greater Mekong Subregion (GMS).
In 2019 he received post-doctoral International Training fellowship from the Wellcome Trust to assess the immune decay after malaria elimination and the risk of malaria resurgence
And a seed grant from Australian Centre of Research Excellence in Malaria Elimination (ACREME) for the project Field evaluation of a point-of-contact device for P. falciparum malaria sero-surveillance
Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
Phyo AP. et al, (2016), The Lancet Infectious Diseases, 16, 61 - 69
Declining Efficacy of Artemisinin Combination Therapy AgainstP. FalciparumMalaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic Factors
Phyo AP. et al, (2016), Clinical Infectious Diseases, 63, 784 - 791
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study
Phyo AP. et al, (2012), The Lancet, 379, 1960 - 1966
Poor response to artesunate treatment in two patients with severe malaria on the Thai–Myanmar border
Phyo AP. et al, (2018), Malaria Journal, 17
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study
Imwong M. et al, (2020), The Lancet Infectious Diseases
Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Saito M. et al, (2020), BMC medicine, 18
Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis.
Saito M. et al, (2020), The Lancet. Infectious diseases
Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?
Ashley EA. and Phyo AP., (2020), The Lancet. Infectious diseases
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
van der Pluijm RW. et al, (2020), The Lancet, 395, 1345 - 1360